Effects of Topical Diclofenac on Tumor Metabolism

Status Completed

Clinical Trial Summary

The rationale of this study is to investigate the effects of topical diclofenac on tumor metabolism in the treatment of actinic keratoses in immunocompetent and immunocompromised patients.

Study hypothesis is that topical diclofenac lowers lactate level in skin biopsies of actinic keratoses. Planned number of patients is 38.

This study is a monocenter study investigating the effects of 3% diclofenac in 2.5% hyaluronic acid gel on tumor metabolism in the treatment of actinic keratoses. Treatment duration is 3 months. Skin biopsies will be obtained before treatment, at the end of the treatment and four weeks after the treatment. Control biopsies at visit 1 and 3 are performed in healthy, sun damaged and untreated skin. Evaluation of efficacy will be performed at the end of the treatment and four weeks after the treatment.

Duration of treatment is 3 months (±4 weeks). Approximately 0,5g Solaraze® 3% gel is applied on a 5cm x 5cm lesion. Solaraze® 3% gel is applied twice daily on the study lesions.

Clinical Trial Description

Neoplastic cells show an increased glucose metabolism and glycolysis which is associated with high lactate concentrations. There is also data for several tumor entities that high levels of lactate in the tumor are associated with tumor progression, metastasis and poor clinical outcome. Kreutz et al. demonstrated that diclofenac inhibits tumor cell proliferation in vitro and tumor growth in vivo via COX-independent effects on glucose metabolism. Diclofenac is taken up by tumor cells and inhibits tumor cell proliferation through inhibition of the oncogene MYC and subsequently glycolysis and block of lactate transport. MYC regulates genes involved in glycolysis and is upregulated in neoplastic cells, which is in line with the metabolic switch to glycolysis, the so called "Warburg effect", that cancer cells show. Although these results were found in vitro using human melanoma cells and in vivo in a mouse model, a similar mechanism of action is assumed to be relevant for the treatment of actinic keratoses with topical diclofenac. However tumor metabolism in diclofenac-treated actinic keratoses has never been investigated. To investigate the mechanism of action of diclofenac in the treatment of actinic keratoses, a clinical study analyzing particularly lactate levels, glycolysis and inflammatory infiltrate is needed. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01935531
Study type	Interventional
Source	University Hospital Regensburg
Contact
Status	Completed
Phase	Phase 4
Start date	June 2013
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03575780` - Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis	Phase 1
Completed	`NCT04085367` - Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face	Phase 3
Completed	`NCT05937529` - Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis	N/A
Completed	`NCT02520700` - A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses	N/A
Terminated	`NCT01538901` - Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients	Phase 4
Completed	`NCT01354717` - Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo	Phase 3
Completed	`NCT00742391` - A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations	Phase 3
Completed	`NCT03285477` - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp	Phase 3
Suspended	`NCT03963102` - Duration of Ameluz Application in Acral Actinic Keratoses Response	Phase 4
Not yet recruiting	`NCT05923060` - Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses	Phase 2
Withdrawn	`NCT06026358` - Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands	Phase 4
Completed	`NCT02622594` - Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times	Phase 4
Completed	`NCT00786994` - The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses	Phase 2
Completed	`NCT00774787` - Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses	Phase 4
Completed	`NCT00544258` - Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005	Phase 1
Completed	`NCT04024579` - Treatment of Actinic Keratosis With 5% KOH Solution
Completed	`NCT04843553` - Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients	Early Phase 1
Completed	`NCT03315286` - Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure	N/A
Completed	`NCT03279328` - Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents	Phase 4
Completed	`NCT02062853` - Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video	N/A